Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Intercell sees rise in Q2 revenues
Intercell has posted a net loss of EUR1.61m for the second quarter of 2011, compared to EUR8.35m for the same period in 2010. The company’s operating loss was
Intercell has posted a net loss of EUR1.61m for the second quarter of 2011, compared to EUR8.35m for the same period in 2010. The company’s operating loss was
The advanced center houses the latest technologies for mixing, compounding, molding and finishing elastomer packaging components. West Marketing and Strategic Business Development vice president Fran DeGrazio said the
The trial evaluating Natroba demonstrated efficacy against permethrin 1% without nit combing. In Phase III clinical studies, Natroba was shown to be more effective at eliminating head lice
The primary endpoint of the trial was the percentage of ‘off time’ during waking hours as measured by patient diary. ‘Off time’ is the functional state when patients’
The increase in sales was primarily due to the increase in company’s main product Xuesaitong in Tianjin City and Yunnan Province and enhanced sales promotion in Yunnan Province.
The study aims to investigate the pharmacokinetics (PK) and safety profile of UX001 in around 24 patients. The study expects to test four different single-dose levels in each
Viagra, an oral therapy for erectile dysfunction, is the citrate salt of sildenafil, a selective inhibitor of cyclic guanosine monophosphate (cGMP)-specific phosphodiesterase type 5 (PDE5). According to the
Under provisions in its Constitution and Procedure, the Prescription Medicines Code of Practice Authority (PMCPA) advertises brief details of all cases where companies are ruled in breach of
The delta analyzer facilitates surgeons by providing key information in just 5-10 minutes which enables surgical team to decide whether platelets, plasma, red blood cells or other blood
The funding was supported under the Small Business Innovation Research (SBIR) program to provide on-going support for Kineta’s work on a new class of antiviral drugs. The antiviral